This Press Release updates numerical list in reference sectionTheralase® validates previous University of Manitoba research ...

Theralase validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCES ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 35 tables and 45 figures, this 111-page report ?Europe Genital Herpes Treatment Market 2022-2032 by Virus Type (HSV-1, ...

Global genital herpes treatment market will reach $5,051.8 million by 2032, growing by 4.7% annually over 2022-2032, driven by the rising prevalence of sexually transmitted diseases, changing ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

The overall market of herpes simplex is expected to boost with the expected launch of emerging therapy, increased awareness, and extensive research in the forecast period (2025-2034). LAS ...

Pregnant former Married at First Sight bride Elizabeth 'Lizzie' Sobinoff has revealed her recent debilitating health ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...

Clinical-stage pharma stock Theralase Technologies (TSXV:TLT) announced a significant breakthrough in the treatment of Herpes ...

Chitosan, a naturally occurring polysaccharide derived from chitin, has demonstrated significant potential as an antiviral ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.